Axovant Sciences LtdLatest Axovant Sciences Ltd News and UpdatesCompany & Industry OverviewsWhat Spark Therapeutics’ Valuation Trend IndicatesSpark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.
Company & Industry OverviewsWhat Spark Therapeutics’ Valuation Trend IndicatesSpark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.
